Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G)

CONCLUSION: Our data show the potential efficacy and acceptable safety profile of FTD/TPI plus bevacizumab for vulnerable patients with pretreated mCRC.PMID:37950903 | DOI:10.1093/oncolo/oyad296

Source: The Oncologist - November 11, 2023 Category: Cancer & Oncology Authors: Yosuke Kito Hisato Kawakami Seiichiro Mitani Shinichi Nishina Toshihiko Matsumoto Takao Tsuzuki Yudai Shinohara Hozumi Shimokawa Ryosuke Kumanishi Takashi Ohta Hiroo Katsuya Takeshi Kawakami Tomohiro Nishina Hiroko Hasegawa Kohei Akiyoshi Yasutaka Chiba K Source Type: research